

Moderna (Spikevax) COVID-19 Vaccine Aftercare Sheet/Immunization Notice

Taiwan Centers for Disease Control, Ministry of Health and Welfare, Apr. 22, 2022

A reminder to parents/guardians from your child's school, _____, in _____ City/County

On _____ yyyy/mm/dd, your child _____ (Grade: ___ Class: ___ Roll Number: _____)

Received the **Moderna (Spikevax) COVID-19 Vaccine** 1st Dose 2nd Dose

Stamp of health department/contracted medical institution:

【After vaccination: What you need to know】

1. The most common side effects that occur after vaccination are **pain, redness, or swelling at the injection site, which usually go away within several days. Other possible reactions include fatigue, headache, muscle ache, fever, chills, joint pain, and nausea.** The frequency of side effects decreases with increasing age, and most reactions are mild and resolved within a few days. Clinical trials show that side effects are **more common after the second dose compared to the first.**
2. Your child **may develop a fever ($\geq 38^{\circ}\text{C}$) after vaccination. This usually goes away within 48 hours.** If a **fever persists for more than 48 hours or your child experiences severe allergic reactions such as difficulty breathing, wheezing, vertigo, fast heartbeat, or rash,** get urgent medical attention to clarify the cause.
3. **Very rare cases of myocarditis and pericarditis have been observed following vaccination with mRNA COVID-19 Vaccine.** These cases have **primarily occurred within 14 days following vaccination, more often after the second vaccination, and more often in younger men.** Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general. However, the benefits of BioNTech (BNT162b2) COVID-19 vaccination for younger people are still considered to outweigh its known risks. Vaccinated individuals who experience symptoms of myocarditis or pericarditis **listed below within the 28 days after vaccination should seek medical attention immediately:**
chest pain, pressure, or discomfort; palpitations (a heartbeat that feels irregular, fluttery, or as if it is skipping a beat); syncope (fainting); shortness of breath; exercise intolerance (for example, becoming out of breath after walking a few steps or being unable to climb stairs).
4. **Inform the doctor of all your child's symptoms, when they appeared, and the date of injection** as a reference for diagnosis. Suspected severe adverse reactions can be reported to the Vaccine Adverse Event Reporting System (<https://www.cdc.gov.tw/-Category/Page/3-aXITBq4ggn5Hg2dveHBg>) via your child's health care provider or local health department.
5. Although vaccination reduces the chance of contracting COVID-19, it is still possible to become infected with SARS-CoV-2. Vaccinated people should continue to follow epidemic prevention guidelines to protect their health.
6. After vaccination, a **COVID-19 Vaccination Record will be issued. Please keep this card in a safe place.** This card must be presented at the second-shot appointment. Once it is filled in with information about both vaccine doses, the card can be used as proof of vaccination.

Your child was not vaccinated with the **Moderna (Spikevax) COVID-19 Vaccine.** (Reason: _____)

(Please return this slip to the school after your child receives a COVID-19 vaccine.)

City/county: _____ School: ___ Grade: ___ Class: ___ Roll number: ___

Student's name : _____ National ID/resident certificate/passport number: _____

Was vaccinated with the **Moderna (Spikevax) COVID-19 vaccine** 1st Dose 2nd Dose on yyyy/mm/dd _____

Stamp of health department/contracted medical institution:

Adverse reactions and frequency rate in the 7 days after each dose, as observed during Phase III clinical trials*

Adverse reactions	Frequency		
	Individuals aged 18 and older	Individuals aged 12 to 17	Individuals aged 6 to 11
Pain at injection site	92%	97%	98.4%
Fatigue	70%	75%	73.1%
Headache	64.7%	78%	62.1%
Muscle ache	61.5%	54%	35.3%
Chills	45.4%	49%	34.6%
Joint aches	46.4%	35%	21.3%
Nausea/Vomiting	23%	29%	29.3%
Axillary swelling/ Tenderness	19.8%	35%	27.0%
Fever (>38°C)	15.5%	14%	25.7%
Injection Site welling	14.7%	28%	22.3%
Redness	10%	26%	24.0%

Adverse reactions from clinical trials and post-authorization experience in individuals aged 6 and up*

Frequency	Adverse reactions
Very common (≥1/10)	Lymphadenopathy; Pain or swelling at the injection site; fatigue; headache; muscle ache; chills; joint aches; pyrexia;; nausea; vomiting
Common (≥1/100~ <1/10)	Rash, hives, or rash at the injection site; delayed injection site reaction
Uncommon (≥1/1,000~ <1/100)	Dizziness, Itchiness at the injection site
Rare (≥1/10,000~ <1/1,000)	Acute peripheral facial paralysis b, Hypoesthesia, Swelling of the face,
Very rare (<1/10,000)	Myocarditis, Pericarditis
Not known	Anaphylaxis, Hypersensitivity

- a. Lymphadenopathy was captured as axillary lymphadenopathy on the same side as the injection site. Other lymph nodes (e.g., cervical, supraclavicular) were affected in some cases.
- b. Throughout the safety follow-up period, acute peripheral facial paralysis (or palsy) was reported by three participants in the Spikevax group and one participant in the placebo group. Onset in the vaccine group participants was 22 days, 28 days, and 32 days after Dose 2.
- c. There were two serious adverse events of facial swelling in vaccine recipients with a history of injection of dermatological fillers. The onset of swelling was reported 1 and 2 days, respectively, after vaccination.

References:

https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf

_____ Regards from your Department of Health

_____ Department of Health

Contact: _____

_____ School

Contact: _____



Taiwan CDC, MOHW cares about you